Disease activity at baseline and after 6 months of methotrexate monotherapy
| PsA N=980 | RA N=1794 | |||
| Baseline | 6 months | Baseline | 6 months | |
| DAS28-CRP, mean (SD) | 4.1 (1.1) | 2.8 (1.1) | 4.5 (1.2) | 2.6 (1.1) |
| Available % | 80 | 63 | 86 | 73 |
| DAS28, mean (SD) | 4.2 (1.3) | 2.9 (1.2) | 4.8 (1.3) | 2.7 (1.3) |
| Available % | 76 | 58 | 84 | 68 |
| Patient-reported pain, mean (SD) | 53 (23) | 32 (25) | 52 (25) | 26 (24) |
| Available % | 86 | 67 | 88 | 75 |
| Patient-reported global health, mean (SD) | 50 (24) | 33 (25) | 50 (25) | 27 (24) |
| Available % | 87 | 67 | 89 | 76 |
| CRP, median (IQR) | 7.0 (13.8) | 4.0 (5.0) | 9.0 (18) | 4.0 (4.4) |
| Available % | 95 | 70 | 98 | 78 |
| Swollen 28-joint count, mean (SD) | 4.1 (4.2) | 1.4 (2.5) | 6.8 (5.2) | 1.5 (2.6) |
| Available % | 93 | 70 | 97 | 78 |
| Tender 28-joint count, mean (SD) | 5.3 (5.1) | 2.2 (3.5) | 7.0 (5.6) | 2.0 (3.5) |
| Available % | 93 | 70 | 97 | 78 |
| Evaluator’s assessment of disease activity, Likert scale | ||||
| Remission, N (%) | 5 (1) | 162 (25) | 10 (1) | 452 (33) |
| Low, N (%) | 179 (20) | 349 (53) | 265 (16) | 639 (47) |
| Moderate, N (%) | 567 (63) | 131 (20) | 890 (54) | 226 (17) |
| High, N (%) | 139 (15) | 17 (3) | 462 (28) | 34 (3) |
| Maximal, N (%) | 7 (1) | 0 | 31 (2) | 0 |
| Available % | 92 | 67 | 92 | 75 |
CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; PsA, psoriatic arthritis; RA, rheumatoid arthritis.